Shareholders are feeling the consequences of the company's dilutive ways.Unity Software (U +1.07%) was one of Wall Street's most exciting IPO stocks in 2020. But after soaring in its market debut, the stock has languished. Years later, Unity's stock traded more than 30% below its debut share price, and has plunged nearly 80% from its all-time high in 2021.The company remains a leading platform for game developers. Unity's ecosystem enables developers to create, manage, and monetize games across console, com ...

Investors were haunted by the specter of share dilution.It isn't unusual for a biotech to raise capital after it posts positive results from a clinical trial. In the case of a new fundraising effort by Dyne Therapeutics (DYN 16.94%), however, investors aren't happy that the biotech is going to the well. Following the announcement of a significant secondary stock issue, market players traded out of Dyne on Tuesday, leaving its shares with a nearly 17% loss.300 million reasons for concernJust after market clo ...

Core Viewpoint - Investor interest in Beyond Meat has been revived by meme stock traders, with shares increasing by 22% over the past week despite a lack of company-specific news [1] Group 1: Stock Performance - Beyond Meat's share price has decreased by 98% since its IPO in May 2019 and is down 67% year to date, even with the recent surge [2] - A significant rally in late October saw the stock rise by 1,400%, raising questions about future upside potential [2] Group 2: Financial Performance - In Q3, Beyond Meat's net revenue fell by 13% to $70.2 million, attributed to weak category demand, reduced U.S. retail distribution, and lower sales to international fast-food restaurants [4] - The company anticipates Q4 revenue between $60 million and $65 million, indicating a potential 15% year-over-year decline at the high end of the guidance [4] Group 3: Debt and Share Dilution - Beyond Meat ended Q3 with $1.3 billion in long-term liabilities and refinanced approximately $900 million of that debt by issuing 318 million shares to bondholders [6] - A charter amendment has increased the number of authorized shares from 500 million to 3 billion, raising concerns about share dilution [6] Group 4: Company Strategy - Beyond Meat is currently in a turnaround phase, focusing on rebuilding its distribution network, cutting costs, and expanding product lines [8] - The financial data and trends indicate significant risks, suggesting that the stock may be more suitable for speculative traders rather than serious investors [8]

SoFi stock price tanked by over 6% in the extended hours as concerns about increased dilution continued. It dropped to $27.7 from the closing price of $30, and 15% below the highest point this year. ...

马斯克过去曾抨击特斯拉股票的做空者，最近还警告比尔・盖茨 "尽快" 平掉他的空头头寸。 尽管伯里警告特斯拉的估值过高，但华尔街却变得越来越看好。上周，Melius Research 将这家电动汽车 制造商列为 "必持" 股票，主要是由于特斯拉在自动驾驶方面的努力，以及首席执行官埃隆・马斯克谈 论其芯片制造进展。此前一周，Stifel 因特斯拉在全自动驾驶 (FSD) 和机器人出租车服务方面的优势， 上调了其目标价并重申了对特斯拉的 "买入" 评级。 近日，特斯拉公布了欧洲主要市场 11 月销量数据，销量下滑进一步恶化，但同时也上演起 "冰火两重 天"。特斯拉在法国的 11 月新车销量大跌 58%，仅略低于 1600 辆。在丹麦，特斯拉销量暴跌 49%; 在 瑞典更是锐减 59%，连续多个季度呈现疲态。 与此同时，挪威成为罕见例外，该国销量已超越其他任何汽车制造商以往的年销量纪录，在距离年终尚 有一个月之际提前创下该国年度销售新高。特斯拉 11 月在挪威的注册量暴增 175%，部分原因是当地 关于未来电动车税收优惠政策的不确定性，促使消费者提前购车。 本文源自：智通财经APP 知名做空者迈克尔・伯里 (Mich ...

Core Viewpoint - The company Iovance Biotherapeutics announced a potentially dilutive capital raising through a secondary issue of common stock, which negatively impacted its share price by nearly 6% [1][2][3]. Group 1: Capital Raising Details - Iovance plans to raise up to $350 million through an at-the-market secondary issue of its common stock, as disclosed in regulatory filings [3]. - Jefferies has been appointed as the sales agency for the flotation, earning a 3% commission on the total gross proceeds [5]. - The proceeds from the capital raising will be used to enhance the commercial prospects of its leading drug, Amtagvi, and to fund investigational programs and general corporate purposes [5]. Group 2: Market Impact and Concerns - The announcement of the capital raising led to a significant drop in Iovance's share price, contrasting with the S&P 500 index's minor decline of 0.4% [2]. - The potential dilution from this capital raising is a legitimate concern, especially given Iovance's current market capitalization of over $915 million [6].

Core Viewpoint - Nektar Therapeutics experienced a decline in stock price following the completion of a secondary stock issue, resulting in a 3% loss, while the S&P 500 index rose by 0.8% [1] Group 1: Capital Raise Details - Nektar completed a secondary share flotation, selling slightly more than 4.89 million shares of common stock, including 638,298 shares sold to underwriters [2] - The gross proceeds from the share issue were approximately $115 million, priced at $23.50 per share, intended for general corporate purposes, including drug development and research activities [4] Group 2: Impact on Shareholders - The secondary share flotation is dilutive to existing shareholders, increasing the total share count from slightly more than 12.4 million to nearly 17.4 million shares, which negatively impacts shareholder value [5] - Investors are concerned about potential future equity offerings, which could lead to further dilution of shares [7] Group 3: Company Pipeline and Potential - Nektar has several pipeline projects in development, with its leading candidate, rezpegaldesleukin, showing promising results for treating moderate-to-severe atopic dermatitis [6]